What is Post-Transfusion Purpura (PTP)?
Post-transfusion purpura (PTP) is a rare but severe immune-mediated transfusion reaction characterized by sudden, profound thrombocytopenia (often <10 × 10³/μL) occurring typically 5-12 days after transfusion of any blood product containing platelets or red blood cells 1, 2.
Pathophysiology
PTP occurs when a patient develops alloantibodies against platelet-specific antigens, most commonly anti-HPA-1a (formerly anti-PlA1), which paradoxically destroy both the transfused incompatible platelets AND the patient's own antigen-negative platelets 1, 2. This paradoxical destruction of autologous platelets remains incompletely understood, though antibodies can be eluted from the patient's own antigen-negative platelets, suggesting a "pseudo-specificity" mechanism 3.
Clinical Presentation
Key Features:
- Timing: Thrombocytopenia develops 5-12 days post-transfusion (peak at days 7-8) 3
- Severity: Platelet counts typically drop precipitously to <10 × 10³/μL, often reaching nadirs of 1-7 × 10³/μL 1, 3, 4
- Bleeding manifestations: Ranges from petechiae and purpura to severe, potentially fatal hemorrhage 2, 5
- Associated symptoms: 85% of patients experience febrile, non-hemolytic transfusion reactions during the precipitating transfusion 3
At-Risk Populations
The classic patient is a multiparous woman (>90% of cases are female) who has been previously alloimmunized during pregnancy 5, 3. The mean age at presentation is approximately 60 years (range 35-78 years) 3. However, PTP can occur in trauma patients receiving massive transfusion protocol, making diagnosis particularly challenging in acute settings 1.
Diagnosis
Confirmation requires demonstrating platelet-specific alloantibodies in the patient's serum, most commonly:
- Anti-HPA-1a (anti-Zwa): Found in 92% of cases 3
- Less commonly: anti-HPA-3a, anti-Bra, anti-Baka, anti-Bakb 3, 6
- May coexist with HLA class I antibodies 6, 4
Critical diagnostic pitfall: The sudden thrombocytopenia can mimic idiopathic thrombocytopenic purpura (ITP), heparin-induced thrombocytopenia (HIT), or thrombotic thrombocytopenic purpura (TTP) 4. The key distinguishing feature is the temporal relationship to recent transfusion (within the preceding 2-14 days).
Management
Intravenous immunoglobulin (IVIG) is the treatment of choice, with 74% of patients responding favorably 3. Additional therapies include:
Critical Management Considerations:
- Platelet transfusions are contraindicated 7—they produce no adequate increment and may provoke severe febrile reactions in 6/20 patients 3
- Surgical interventions and anticoagulation may need to be held during the acute phase 1
- Multidisciplinary coordination between transfusion medicine, hematology, and surgical teams is essential 1
Natural History
Without treatment, thrombocytopenia typically resolves spontaneously over 10-17 days, with platelet counts recovering to >50 × 10³/μL by day 14 and >100 × 10³/μL by day 17 3. However, mortality from hemorrhagic complications occurs in approximately 5% of cases 3, making prompt recognition and treatment critical.
Future Transfusion Considerations
Recurrence is rare, but patients with documented PTP should receive antigen-negative blood products for all future transfusions 2. For HPA-1a alloimmunized patients, this means HPA-1a negative platelets if platelet transfusion becomes necessary.